Adrian V. S. Hill

Sir Adrian Vivian Sinton Hill, KBE FRS FMedSci FRCP (born 9 October 1958)[2] is a British-Irish vaccinologist who is Director of the Jenner Institute and Lakshmi Mittal and Family Professor of Vaccinology at the University of Oxford, an honorary Consultant Physician in Infectious Diseases,[3] and Fellow of Magdalen College, Oxford.[4] Hill is a leader in the field of malaria vaccine development and was a co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine, along with Professor Sarah Gilbert of the Jenner Institute and Professor Andrew Pollard of the Oxford Vaccine Group.[5][1][6]

Sir Adrian Hill
Born (1958-10-09) 9 October 1958 (age 65)
EducationBelvedere College
Alma mater
Known forVaccinology
Spouses
  • (m. 1994; div. 2020)
  • (m. 2021)
Scientific career
FieldsGenetics
Immunology
Vaccines
Malaria[1]
Institutions
ThesisThe distribution and molecular basis of thalassaemia in Oceania (1986)
Doctoral advisorJohn Brian Clegg
David Weatherall
Websitewww.ox.ac.uk/news-and-events/find-an-expert/professor-adrian-hill Edit this at Wikidata

Early life and education

Hill was educated at Belvedere College in Dublin.[2] He began reading medicine at Trinity College Dublin, where he was elected a Foundation Scholar in 1978.[7] Thereupon he transferred to Magdalen College, Oxford for one year, but he ended up remaining in Oxford to complete the rest of his medical degree, qualifying in 1982.[8][4] He remained at the University of Oxford for postgraduate studies and was awarded a Doctor of Philosophy degree in 1986[9] for research on the molecular genetics of thalassemia supervised by John B. Clegg [Wikidata].[4][10]

Career and research

During his time at the Wellcome Trust Centre for Human Genetics his research group studied genetic susceptibility to infections such as malaria, tuberculosis, and HIV. From 1997 [11] he has developed candidate vaccines for malaria which produce cellular (T-cell) immunity and partial efficacy using Adenovirus and Modified vaccinia Ankara (MVA) viral vector vaccines in a prime-boost regime.[12] From 2005 he has played a leading role in the pre-clinical and clinical assessment of new chimpanzee adenoviral vaccine vectors, particularly ChAd63, ChAd3 and ChAdOx1.

His group has developed numerous candidate vaccines against malaria which have been tested in clinical trials in the UK and Africa.[13] In 2021 his group reported high efficacy of a new R21/matrix-M candidate vaccine in Burkina Faso children and this vaccine is now in a phase III licensure trial.[14] In 2014, he led a clinical trial of an Ebola vaccine based on chimpanzee adenoviral and MVA vector technology in response to the West African Ebola virus epidemic.[12][15][16] In 2016 he co-founded Vaccitech plc, an Oxford University spin-off company developing therapeutic and preventive vaccines based on viral vector technology.[17] In 2017 he led a successful major award application to Innovate UK to co-found the Vaccines Manufacturing and Innovation Centre (VMIC) in Harwell, Oxfordshire, one of the first purpose-built vaccine manufacturing centres for emergency response vaccines.[18] In response to the 2020 COVID-19 pandemic he worked with many others at Oxford to develop and partner the ChAdOx1 vector-based SARS-CoV-2 vaccine, notably with AstraZeneca and the Serum Institute of India, supporting large scale access for low and middle income countries.[19]

Honours and awards

Personal life

Hill has two children with his former wife, epidemiologist Sunetra Gupta.

In 2021, he married Sabina Murray.[2]

References